BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Luc Biedermann  1     Alex Straumann  2     Alfredo J. Lucendo  3     Stephan Miehlke  4     Michael Vieth  5     Christoph Schlag  1     Cecilio Santander  6     Constanza Ciriza de Los Rios  7     Christoph Schmöcker  8     Ahmed Madisch  9     Petr Hruz  10     Jamal Hayat  11     Ulrike von Arnim  12     Arjan Bredenoord  13     Stefan Schubert  14     Ralph Mueller  15     Roland Greinwald  15     Alain M. Schoepfer  16     Stephen E. Attwood  17    
1 USZ Zürich, Zürich, Switzerland
2 Swiss EoE Research Network, Olten, Switzerland
3 Hospital General de Tomelloso, Tomelloso, Spain
4 Internal Medicine Center Eppendorf, Hamburg, Germany
5 Friedrich-Alexander-University Erlangen-Nuremberg / Klinikum Bayreuth, Bayreuth, Germany
6 Hospital Universitario de la Princesa, Madrid, Spain
7 Hospital 12 de Octubre Dept. de Gastroenterologia, Madrid, Spain
8 Ruppiner Kliniken, Brandenburg Medical School, Neuruppin, Germany
9 CRH Clinic Hannover, Hannover, Germany
10 Clarunis, Basel, Switzerland
11 St. George`s University Hospitals, London, United Kingdom
12 Otto-Von Guericke University, Madgeburg, Germany
13 Amsterdam UMC, Amsterdam, Netherlands
14 Gastroenterologist in private practice, Berlin, Germany
15 Dr. Falk Pharma GmbH, Freiburg, Germany
16 University Hospital (CHUV), Lausanne, Switzerland
17 Durham University, North Tyneside, United Kingdom

Topic
Neurogastroenterology & Motility, Oesophagus

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing